Skip to main content

T-VEC plus pembrolizumab yields promising response rate in phase 2 sarcoma study

Primary tabs

View
Get Stamp Tags
Published Locations

Breadcrumb

Home
T-VEC plus pembrolizumab yields promising response rate in phase 2 sarcoma study

User login

Username

Password

Reset your password

Type	Lead	score